Funds Lotame Secures $15 Million in Series D Funding

FUND Lotame, the world’s leading independent data management platform (DMP), has announced that it has secured $15 million in Series D funding.

INVESTORS The round was led by Sozo Ventures and TrueBridge Capital Partners, with substantial participation from existing investors Battery Ventures, Emergence Capital Partners and RJ Finlay & Co.

TARGET Combined with previous funding rounds, Lotame has now

raised a total of $44 million. The additional financing will allow Lotame to accelerate the development of its innovative real-time, cross-device data platform and extend its position as the largest and fastest growing independent pure-play DMP.

THE COMPANY Lotame is the DMP for Maximum Audience Impact— helping marketers, publishers and agencies maximize the way they collect, unify, protect, and activate audience data. Leveraging the industry’s most robust audience management engine, they’re able to intelligently monetize data, create premium properties, target more efficiently, and drive higher campaign performance and revenue.

Name Lotame

Target

Accelerate the development of its innovative real-time, cross-device data platform and extend its position as the largest and fastest growing independent pure-play DMP.

Investors

Sozo Ventures, TrueBridge Capital Partners, Battery Ventures, Emergence Capital Partners and RJ Finlay & Co.

Thesan Pharmaceuticals $49M Series B Financing Name

Thesan Pharmaceuticals Target

Development of new chemical entities with novel mechanisms of action.

Investors Novo Ventures, SV Life Sciences and Lundbeckfond Ventures.

FUND Biotechnology Company, Thesan Pharmaceuticals recently announced the closing of a $49M Series B financing.

INVESTORS The fudning was led by Novo Ventures (a current Investor), with SV Life Sciences and Lundbeckfond Ventures joining the syndicate.

TARGET “Our focus remains the development of new chemical entities

with novel mechanisms of action. All drug candidates in our expanded pipeline are NCEs and new targets,” said Gordon Foulkes, Thesan’s CEO. “We are very pleased with the deep financial backing provided by four top tier venture funds, which puts us in an unparalleled position as a biopharma to develop new drugs in this area.”

THE COMPANY Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.

GC Aesthetics raises $60M

FUND GC Aesthetics, one of the largest independent aesthetic companies globally, has raised $60M in funding.

INVESTORS The company raised $40M of financing from new investor OrbiMed, alongside nearly $20M from existing investors including Montreux Equity Partners and Oyster Capital.

TARGET Ayse Kocak, CEO of GC Aesthetics and the industry’s first-ever female CEO says: “We are delighted to have secured this funding that will allow GC Aesthetics to consolidate its position as a market leader in aesthetics, and one which continues to keep women’s interests at the forefront of all our goals. This has

been an exciting year for us and we have laid the foundations to launch groundbreaking initiatives. This funding will enable us to maximise further growth, introduce our quality products to new markets and give patients and surgeons more choice than ever before”.

THE COMPANY GC Aesthetics, which stands for Global Consolidated Aesthetics, was founded in 2007 and is the umbrella company for two leading implant manufacturers: Nagor and Eurosilicone. The Dublin-based privately owned company has more than 60 years of combined experience and excellence in implant development, manufacture and innovation and currently manufactures and sells breast implants in 90 countries, offering a wide product range with nearly 600 types of implant.

Name GC Aesthetics

Target Allow GC Aesthetics to consolidate its position as a market leader in aesthetics, and one which continues to keep women’s interests at the forefront of all our goals.

Investors OrbiMed, Montreux Equity Partners and Oyster Capital.

63